~~<i id='97848E6358'><strike id='97848E6358'><tt id='97848E6358'><pre id='97848E6358'></pre></tt></strike></i>~~

Home» explore» comprehensive

comprehensive

author：entertainment 2025-09-28 05:54:14 Page View：769

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Everything to know for the next Powerball drawing as jackpot hits $1 billion
Next article： Novavax promises a turnaround & Lilly roils the obesity market

leisure time

Medical records are filled with copy

AdobeIrecentlytookcareofapatientwhosemedicalrecordsincludedmultiplenotesaboutherpastopen-heartsurger

Argenx drug significantly slows progression of nerve disorder

AdobeBelgiandrugmakerArgenxsaidMondaythatitsantibodytreatmentcalledVyvgartsignificantlydelayedthepro

Malaria cases in Florida and Texas: Here’s what you need to know

MosquitoscaughtfortestingawaitshipmenttoalabinMcAllen,Texas,inApril2016tobetestedformosquito-bornedi

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

7:36JonHuntsmanlistenstoquestionsduringahearingaboutvotingrightsintheDistrictofColumbiabeforetheCons